about
Doppler velocimetry and cytofluorimetric analysis in uterine myomas.Color Doppler velocimetry and three-dimensional color power angiography of cervical carcinoma.From bio-molecular and technology innovations to clinical practice: focus on ovarian cancer.Cyclo-oxygenase-2 (Cox-2) expression and resistance to platinum versus platinum/paclitaxel containing chemotherapy in advanced ovarian cancer.Phase I study of gemcitabine and liposomal doxorubicin in relapsed ovarian cancer.Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients.Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective study.Chemoradiation with concomitant boost followed by radical surgery in locally advanced cervical cancer: a dose-escalation study.Phase II study of the combination carboplatin plus celecoxib in heavily pre-treated recurrent ovarian cancer patients.Dose-dense FEC followed by dose-dense ixabepilone as neoadjuvant treatment for breast cancer patients: a feasibility study.Standardized sample preparation phases for a quantitative measurement of plasma peptidome profiling by MALDI-TOF.Femur metastasis in carcinoma of the uterine cervix: a rare entity.Solitary pancreatic lymph node metastasis from carcinoma of the breast: case report.Clinical utility of trabectedin for the treatment of ovarian cancer: current evidence.Neuroendocrine stress response in patients undergoing benign ovarian cyst surgery by laparoscopy, minilaparotomy, and laparotomy.Class III beta-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients.Metronomic oral cyclophosphamide (MOC) in the salvage therapy of heavily treated recurrent ovarian cancer patients: a retrospective, multicenter studyExpression of nucleoside transporters, deoxycitidine kinase, ribonucleotide reductase regulatory subunits, and gemcitabine catabolic enzymes in primary ovarian cancer.Vulvar squamous cell carcinoma with sarcoma-like stroma: a case report and review of the literatureGemcitabine: current role and future options in the treatment of ovarian cancer.Polarisation of Tumor-Associated Macrophages toward M2 Phenotype Correlates with Poor Response to Chemoradiation and Reduced Survival in Patients with Locally Advanced Cervical Cancer.Cathepsin D assay in ovarian cancer: correlation with pathological features and receptors for oestrogen, progesterone and epidermal growth factor.Epidermal growth factor, oestrogen and progesterone receptor expression in primary ovarian cancer: correlation with clinical outcome and response to chemotherapy.Immunoradiometric and immunohistochemical analysis of Cathepsin D in ovarian cancer: lack of association with clinical outcomePrognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma.Malignant transformation of Madelung's disease in a patient with a coincidental diagnosis of breast cancer: a case report.Hormone receptor expression profile of low-grade serous ovarian cancers.Relationship between cathepsin-D content and disease-free survival in node-negative breast cancer patients: a meta-analysis.Intensity-modulated extended-field chemoradiation plus simultaneous integrated boost in the pre-operative treatment of locally advanced cervical cancer: a dose-escalation studySurvivin expression in ovarian cancer and its correlation with clinico-pathological, surgical and apoptosis-related parameters.p53 overexpression is associated with cytoreduction and response to chemotherapy in ovarian cancer.hMSH2 and GTBP expression in advanced stage epithelial ovarian cancer.Expression of cyclooxygenase-2 (COX-2) in tumour and stroma compartments in cervical cancer: clinical implicationsPhase II study of liposomal doxorubicin and gemcitabine in the salvage treatment of ovarian cancer.miR-30a inhibits endothelin A receptor and chemoresistance in ovarian carcinoma.Progestin-releasing intrauterine device insertion plus palliative radiotherapy in frail, elderly uterine cancer patients unfit for radical treatment.Conservatively treated glassy cell carcinoma of the cervix.Extracranial radiosurgery with volumetric modulated arc therapy: Feasibility evaluation of a phase I trialRole of CT scan-based and clinical evaluation in the preoperative prediction of optimal cytoreduction in advanced ovarian cancer: a prospective trial.Biomarker analysis of the MITO2 phase III trial of first-line treatment in ovarian cancer: predictive value of DNA-PK and phosphorylated ACC.
P50
Q33193713-AA2FE9D1-6D44-4C1B-9639-DAC4117F7688Q33206367-9F1573BD-848C-4CD5-A819-1B5ADE1E79DAQ33246073-B7A7A584-7507-402A-AD69-A74173F94D54Q33249461-54031960-3D0C-4541-84F3-77A5B3C1682DQ33341667-CA663410-5F53-449F-8BE1-FED024E700BAQ33348914-527801B5-EF04-4CFC-B506-5CC4B6274F4EQ33365433-CBCE91B1-379F-4268-888B-ADC0B8C2EC48Q33379856-8E5C7D85-CB7E-455E-BAFC-6476AF0BAE08Q33395587-CD54D7BE-BDB5-4DE3-A7F1-38EB99155C41Q33409728-816B4A5E-1E24-4DA4-A7AD-878657F3E6DEQ33540528-BA0ADF41-09A2-4199-A521-61B1DC491C39Q33767178-6B03474C-C60D-4D9E-A8BE-B3B91A86FBF5Q33895102-D7797A70-FA5A-42C1-9CED-98E1C151A63EQ33921802-6871EA3B-24E2-4614-8635-F45EADFB394FQ34195078-9D5729D5-A3D3-431E-85DE-FD9190E6C91EQ34522032-76A3F669-BD55-4902-A955-E870FE1FC231Q34993605-F2BB8591-0107-4650-9CA2-5A012A7F9978Q34994625-02E51232-46F8-44B3-A736-77D08F7D1FEFQ35339021-1DB4958E-89D8-48E8-BFC7-9A5798E1A4EFQ35571464-0358C5F4-AA2B-48AD-AFA5-E0ED27CA2D4FQ35763382-7B3BF3A8-BDC9-47F1-AFAC-E1BC33C2CAF5Q35992862-195C3582-7DB0-4422-9273-CF58B8118B6AQ36081524-EEB95B64-0295-4DA6-8FBE-811BF3509E54Q36115828-905B728C-EEB5-4A0D-BCE7-AE30CD2C9713Q36138893-605B66DD-E0FC-42EB-85B7-2FB2302296DCQ36253751-1884852D-D60A-46DD-9999-A9FB461CBBBEQ36287850-436273FB-5BB4-4F42-87C0-160F5E6E2C7BQ36431062-897F5B2B-7095-4017-A6DC-FBF569AC52A9Q36550570-C31FB348-601C-44B6-B0DC-067B332AAD74Q36616161-9076041C-194C-4B5E-8609-24E73DB0898AQ36619706-64482620-0E01-4B16-A16B-6465CE6FAA58Q36620488-BBB2E1AE-63EB-4BFC-B151-B5C35EF764D4Q36646238-720B8A11-939F-4150-A1BD-314A13115FFFQ36671058-D147EABB-CD1B-45B3-9111-3E2579E7F861Q36782334-C4C02D7B-102E-457C-AE9E-1D6392B9CCBCQ36825389-0B426307-7743-4728-8CA8-924FEE1A4EBFQ36870260-90D734A1-AADE-41A0-A444-11AA22A11F21Q36980782-32F9C179-0B09-465C-AA9E-56BE14BFAC7FQ37400561-007BB314-B093-4167-9433-319AEC4A70C0Q37687273-EBC803C9-527E-484C-8F02-953884E645B5
P50
description
Forscher
@de
chercheur
@fr
investigador
@es
researcher
@en
ricercatore
@it
wetenschapper
@nl
研究者
@zh
name
G Ferrandina
@ast
G Ferrandina
@en
G Ferrandina
@es
G Ferrandina
@nl
type
label
G Ferrandina
@ast
G Ferrandina
@en
G Ferrandina
@es
G Ferrandina
@nl
prefLabel
G Ferrandina
@ast
G Ferrandina
@en
G Ferrandina
@es
G Ferrandina
@nl
P31
P496
0000-0003-4672-4197